John A. Kanis
Auto-generated profile, based on publicly available information

John A. Kanis

Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2006 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
OJO. Johnell
O. Johnell
JKJ. A. Kanis
J. A. Kanis

11 October 2013 in Archives of Osteoporosis
Verified
Journal Article
Open access
PDF file
EHE. Hernlund
E. Hernlund
ASA. Svedbom
A. Svedbom
MIM. Ivergård
M. Ivergård
JCJ. Compston
J. Compston
CCC. Cooper
C. Cooper
JKJ. A. Kanis
J. A. Kanis
Summary This report describes the epidemiology, burden, and treatment of osteoporosis in the 27 countries of the European Union (EU27). Introduction Osteoporosis is characterized by reduced bone mass and disruption of bone architecture, resulting in increased risk of fragility fractures which represent the main clinical consequence of the disease. Fragility fractures are associated with substantial pain and suffering, disability and even death for affected patients and substantial costs to society. The aim of this report was to characterize the burden of osteoporosis in the EU27 in 2010 and beyond. Methods The literature on fracture incidence and costs of fractures in the EU27 was reviewed and incorporated into a model estimating the clinical and economic burden of osteoporotic fractures in 2010. Results Twenty-two million women and 5.5 million men were estimated to have osteoporosis; and 3.5 million new fragility fractures were sustained, comprising 610,000 hip fractures, 520,000 vertebral fractures, 560,000 forearm fractures and 1,800,000 other fractures (i.e. fractures of the pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum and other femoral fractures). The economic burden of incident and prior fragility fractures was estimated at € 37 billion. Incident fractures represented 66 % of this cost, long-term fracture care 29 % and pharmacological prevention 5 %. Previous and incident fractures also accounted for 1,180,000 quality-adjusted life years lost during 2010. The costs are expected to increase by 25 % in 2025. The majority of individuals who have sustained an osteoporosis-related fracture or who are at high risk of fracture are untreated and the number of patients on treatment is declining. Conclusions In spite of the high social and economic cost of osteoporosis, a substantial treatment gap and projected increase of the economic burden driven by the aging populations, the use of pharmacological interventions to prevent fractures has decreased in recent years, suggesting that a change in healthcare policy is warranted.

22 February 2008 in Osteoporosis International
Verified
Journal Article
Open access
PDF file
JKJ. A. Kanis
J. A. Kanis
OJO. Johnell
O. Johnell
AOA. Oden
A. Oden
HJH. Johansson
H. Johansson
EME. McCloskey
E. McCloskey
A fracture risk assessment tool (FRAX™) is developed based on the use of clinical risk factors with or without bone mineral density tests applied to the UK.

1 June 2002 in The Lancet
Verified
Journal Article
Closed access
JKJohn A Kanis
John A Kanis

1 June 2005 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
CLC. De Laet
C. De Laet
JKJ. A. Kanis
J. A. Kanis
AOA. Odén
A. Odén
HJH. Johanson
H. Johanson
OJO. Johnell
O. Johnell
ATA. Tenenhouse
A. Tenenhouse

15 March 2012 in Osteoporosis International
Verified
Journal Article
Open access
PDF file
JKJ. A. Kanis
J. A. Kanis
AOA. Odén
A. Odén
EME. V. McCloskey
E. V. McCloskey
HJH. Johansson
H. Johansson
DWD. A. Wahl
D. A. Wahl
OLon behalf of the IOF Working Group on Epidemiology and Quality of Life
on behalf of the IOF Working Group on Epidemiology and Quality of Life
Summary The country-specific risk of hip fracture and the 10-year probability of a major osteoporotic fracture were determined on a worldwide basis from a systematic review of literature. There was a greater than 10-fold variation in hip fracture risk and fracture probability between countries. Introduction The present study aimed to update the available information base available on the heterogeneity in the risk of hip fracture on a worldwide basis. An additional aim was to document variations in major fracture probability as determined from the available FRAX models. Methods Studies on hip fracture risk were identified from 1950 to November 2011 by a Medline OVID search. Evaluable studies in each country were reviewed for quality and representativeness and a study (studies) chosen to represent that country. Age-specific incidence rates were age-standardised to the world population in 2010 in men, women and both sexes combined. The 10-year probability of a major osteoporotic fracture for a specific clinical scenario was computed in those countries for which a FRAX model was available. Results Following quality evaluation, age-standardised rates of hip fracture were available for 63 countries and 45 FRAX models available in 40 countries to determine fracture probability. There was a greater than 10-fold variation in hip fracture risk and fracture probability between countries. Conclusions Worldwide, there are marked variations in hip fracture rates and in the 10-year probability of major osteoporotic fractures. The variation is sufficiently large that these cannot be explained by the often multiple sources of error in the ascertainment of cases or the catchment population. Understanding the reasons for this heterogeneity may lead to global strategies for the prevention of fractures.